Lovastatin

"Lovastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.

Descriptor ID	D008148
MeSH Number(s)	D02.455.426.559.847.638.400 D04.615.638.400
Concept/Terms	Lovastatin Lovastatin Mevinolin Monacolin K 6-Methylcompactin 6 Methylcompactin MK-803 MK-803 MK 803 MK803 Mevacor Mevacor Lovastatin, (1 alpha(S))-Isomer Lovastatin, (1 alpha(S))-Isomer Lovastatin, 1 alpha-Isomer Lovastatin, 1 alpha-Isomer 1 alpha-Isomer Lovastatin Lovastatin, 1 alpha Isomer alpha-Isomer Lovastatin, 1

Below are MeSH descriptors whose meaning is more general than "Lovastatin".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Polycyclic Aromatic Hydrocarbons [D02.455.426.559.847]
Naphthalenes [D02.455.426.559.847.638]
Lovastatin [D02.455.426.559.847.638.400]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Naphthalenes [D04.615.638]
Lovastatin [D04.615.638.400]

Below are MeSH descriptors whose meaning is related to "Lovastatin".

Below are MeSH descriptors whose meaning is more specific than "Lovastatin".

Lovastatin
Simvastatin

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lovastatin" by people in this website by year, and whether "Lovastatin" was a major or minor topic of these publications.

Bar chart showing 38 publications over 21 distinct years, with a maximum of 3 publications in 1995 and 2004 and 2005 and 2008 and 2018

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	1	1
1995	0	3	3
1997	1	1	2
1998	2	0	2
1999	1	0	1
2000	1	0	1
2001	1	0	1
2002	1	0	1
2003	1	1	2
2004	2	1	3
2005	3	0	3
2006	2	0	2
2007	0	1	1
2008	3	0	3
2009	1	1	2
2010	1	0	1
2012	0	2	2
2013	0	1	1
2018	3	0	3
2019	1	0	1
2020	2	0	2

Below are the most recent publications written about "Lovastatin" by people in Profiles.

Aranow C, Cush J, Bolster MB, Striebich CC, Dall'era M, Mackay M, Olech E, Frech T, Box J, Keating R, Wasko MC, St Clair W, Kivitz A, Huang W, Ricketts P, Welch B, Callahan S, Spychala M, Boyle K, York K, Keyes-Elstein L, Goldmuntz E, Diamond B, Davidson A. A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology (Oxford). 2020 07 01; 59(7):1505-1513.

View in: PubMed
Fernandez K, Spielbauer KK, Rusheen A, Wang L, Baker TG, Eyles S, Cunningham LL. Lovastatin protects against cisplatin-induced hearing loss in mice. Hear Res. 2020 04; 389:107905.

View in: PubMed
Christie CF, Fang D, Hunt EG, Morris ME, Rovini A, Heslop KA, Beeson GC, Beeson CC, Maldonado EN. Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content. FASEB J. 2019 07; 33(7):8186-8201.

View in: PubMed
Mazza A, Lenti S, Schiavon L, Di Giacomo E, Tomasi M, Manunta R, Torin G, Townsend DM, Rubello D. Effect of Monacolin K and COQ10 supplementation in hypertensive and hypercholesterolemic subjects with metabolic syndrome. Biomed Pharmacother. 2018 09; 105:992-996.

View in: PubMed
Feng WW, Kuang SY, Tu C, Ma ZJ, Pang JY, Wang YH, Zang QC, Liu TS, Zhao YL, Xiao XH, Wang JB. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. Biomed Pharmacother. 2018 Mar; 99:325-333.

View in: PubMed
Singh I, Samuvel DJ, Choi S, Saxena N, Singh AK, Won J. Combination therapy of lovastatin and AMP-activated protein kinase activator improves mitochondrial and peroxisomal functions and clinical disease in experimental autoimmune encephalomyelitis model. Immunology. 2018 07; 154(3):434-451.

View in: PubMed
Paintlia AS, Paintlia MK, Singh AK, Singh I. Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-a-dependent mechanism. Glia. 2013 Sep; 61(9):1500-1517.

View in: PubMed
Cayo MA, Cai J, DeLaForest A, Noto FK, Nagaoka M, Clark BS, Collery RF, Si-Tayeb K, Duncan SA. JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology. 2012 Dec; 56(6):2163-71.

View in: PubMed
Paintlia AS, Paintlia MK, Hollis BW, Singh AK, Singh I. Interference with RhoA-ROCK signaling mechanism in autoreactive CD4+ T cells enhances the bioavailability of 1,25-dihydroxyvitamin D3 in experimental autoimmune encephalomyelitis. Am J Pathol. 2012 Sep; 181(3):993-1006.

View in: PubMed
Paintlia AS, Paintlia MK, Singh AK, Orak JK, Singh I. Activation of PPAR-? and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells. Glia. 2010 Nov 01; 58(14):1669-85.

View in: PubMed

People

Explore

Similar Concepts

Top Journals